Avita Medical (RCEL) has had the highest return since 1990 by a US stock in the Biotechnology Industry, returning 1,082,400%.
| ASSET | % RETURN |
|---|---|
Avita Medical (RCEL) | 1,082,400% |
Immatics (IMTX) | 230,100% |
Altimmune (ALT) | 105,072.41% |
Evogene (EVGN) | 100,614.29% |
MDxHealth SA ADR (MDXH) | 84,333.33% |
Amgen (AMGN) | 48,795.18% |
Lixte Biotechnology (LIXT) | 41,566.67% |
Gilead Sciences (GILD) | 35,988.59% |
Mesoblast (MESO) | 34,275% |
Vertex Pharmaceuticals (VRTX) | 9,709.1% |
United Therapeutics (UTHR) | 8,149.06% |
Regencell Bioscience (RGC) | 7,468.08% |
Biogen (BIIB) | 6,433.33% |
XORTX Therapeutics (XRTX) | 6,049.73% |
Incyte (INCY) | 5,059.47% |
Alnylam Pharmaceuticals (ALNY) | 4,850.49% |
argenx NV ADR (ARGX) | 4,570.34% |
Azitra (AZTR) | 4,007.14% |
MiMedx (MDXG) | 3,580% |
Krystal Biotech (KRYS) | 2,843.14% |
Regeneron Pharmaceuticals (REGN) | 2,717.55% |
Alaunos Therapeutics (TCRT) | 2,614.29% |
Halozyme Therapeutics (HALO) | 1,674.4% |
Insmed (INSM) | 1,195.88% |
Neurocrine Biosciences (NBIX) | 1,166.4% |